The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
SGLT2 inhibition — a novel strategy for diabetes treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Long-Term Complications of Diabetes Mellitus
Nathan, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282306 · Cited by 1,495
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Cited by
Recent Advances in the Chemical Synthesis of C-Glycosides
Yang, Y., & Yu, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00234 · Cited by 664
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Natural Products for the Treatment of Type 2 Diabetes Mellitus
Ríos, J., Francini, F., & Schinella, G. (2015) · Planta Medica · doi:10.1055/s-0035-1546131 · Cited by 446
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease
Gilbert, R. E. (2017) · Diabetes · doi:10.2337/db16-0796 · Cited by 362
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Alam, S., Hasan, M. K., Neaz, S., Hussain, N., Hossain, M. F., & Rahman, T. (2021) · Diabetology · doi:10.3390/diabetology2020004 · Cited by 323
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Glucose transport families SLC5 and SLC50
Wright, E. M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.002 · Cited by 301
Diabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 287
Jabbour, S. A., Hardy, E., Sugg, J., Parikh, & for the Study 10 Group (2014) · Diabetes Care · doi:10.2337/dc13-0467 · Cited by 286
Sa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Evaluating All Potential Oral Complications of Diabetes Mellitus
Verhulst, M. J. L., Loos, B. G., Gerdes, V. E. A., & Teeuw, W. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00056 · Cited by 276
GLUT, SGLT, and SWEET: Structural and mechanistic investigations of the glucose transporters
Deng, D., & Yan, N. (2016) · Protein Science · doi:10.1002/pro.2858 · Cited by 275
The impact of sugar consumption on stress driven, emotional and addictive behaviors
Jacques, A., Chaaya, N., Beecher, K., Ali, S. A., Belmer, A., & Bartlett, S. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.021 · Cited by 271
“fects on type 2 diabetes, decreases the caloric balance and improves symptoms of diabetes, including obesity in mice fed on 20% glucose or sucrose solution (Tahara et al., 2018; Chao and Henry, 2010) A recent review detailing the current management for type 2 dia-”
BackgroundCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Zhang, X.-Y., Chen, J., Yi, K., Peng, L., Xie, J., Gou, X., Peng, T., & Tang, L. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1842990 · Cited by 260
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1087 · Cited by 243
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Sodium—Glucose cotransporter inhibitors and oxidative stress: An update
Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.26760 · Cited by 167
Clinically and pharmacologically relevant interactions of antidiabetic drugs
May, M., & Schindler, C. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816638050 · Cited by 160
Schwaiger, E., Burghart, L., Signorini, L., Ristl, R., Kopecky, C., Tura, A., Pacini, G., Wrba, T., Antlanger, M., Schmaldienst, S., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15223 · Cited by 133
Regional distribution of SGLT activity in rat brain in vivo
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Diez-Sampedro, A., Kepe, V., Satyamurthy, N., Huang, S.-C., Wright, E. M., & Barrio, J. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2012 · Cited by 126
Tsai, W.-H., Chuang, S.-M., Liu, S.-C., Lee, C.-C., Chien, M.-N., Leung, C.-H., Liu, S.-J., & Shih, H.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94945-4 · Cited by 113
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
Fukudo, S., Endo, Y., Hongo, M., Nakajima, A., Abe, T., Kobayashi, H., Nakata, T., Nakajima, T., Sameshima, K., Kaku, K., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30165-1 · Cited by 50
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., Azoulay, L., & Patorno, E. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15196 · Cited by 39
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Seidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.303 · Cited by 25
Strain, W. D., & Griffiths, J. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.292 · Cited by 16
Metadata
- Authors
- Chao, E. C., & Henry, R. R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-05-28
- Volume
- 9
- Issue
- 7
- Pages
- 551-559
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1974115114
- Cited by
- 822
- References
- 35
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.